MOG and myeloid sarcoma: The latter results are compliant with those of Zafranskaya et al. (41), who compared 3H-thymidine incorporation and CFSE-based assay for assessing MOG-reactive T cells in healthy donors, untreated MS patients and IFN-β-treated patients.